BELLUS Health is a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of chronic cough and other hypersensitization-related disorders.

The Company’s lead product candidate, BLU-5937, is being developed for the treatment of chronic cough and chronic pruritus. 

In July 2019, the Company announced that the first patient had been enrolled in the Phase 2 study of BLU-5937 for the treatment of refractory chronic cough. The Phase 2 study will evaluate the efficacy of BLU-5937 and is expected to add to the Phase 1 evidence showing little to no impact on taste. Top-line results are expected in mid-2020. The Company also announced in July 2019 that it was expanding the BLU-5937 P2X3 antagonist platform to chronic pruritus. A Phase 2 study in chronic pruritus associated with atopic dermatitis ("AD"), also known as eczema, is expected to be initiated in 2020.

BELLUS Health is based in Laval, Quebec and its shares trade under the ticker BLU on the Toronto Stock Exchange.

Share this

Sign up for email alerts

Email Address *
Enter the code shown above.